Sodium valproate versus phenytoin monotherapy for epilepsy: An individual participant data review

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 8, 2018, Pages

  Nevitt, Sarah J ^a   Marson, Anthony G ^a   Weston, Jennifer ^a   Tudur Smith, Catrin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; VALPROIC ACID; ANTICONVULSIVE AGENT;

ACNE; ALOPECIA; ANOREXIA; ATAXIA; BLOOD DYSCRASIA; BODY WEIGHT GAIN; CLINICAL OUTCOME; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DYSARTHRIA; DYSPEPSIA; EDEMA; ERYTHRODERMA; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; HAIR LOSS; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERPLASIA; JAUNDICE; LEG DISEASE; LETHARGY; MYALGIA; NAUSEA; NYSTAGMUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SKIN ALLERGY; SOMNOLENCE; SYSTEMATIC REVIEW; TIME TO TREATMENT; TONIC CLONIC SEIZURE; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; UNSTEADINESS; VOMITING; GENERALIZED EPILEPSY; META ANALYSIS; SEIZURE;

ANTICONVULSANTS; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; HUMANS; PHENYTOIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 85051284074     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001769.pub4     Document Type: Review

References (105)

1. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 1985;48:639-44. 3168972
2. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994;35(2):381-90. 3168974
3. Czapinski P, Terczynski A, Czapinska E. Randomised 36-month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia 1997;38(Suppl 3):42. 3168976
4. De Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BGR, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-13. 3168978
5. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology 1991;33:524-34. 3168980
6. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick DW, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry 1995;58:44-50. 3168982
7. Ramsay RE, Wilder BJ, Murphy JV, Holmes GL, Uthman B, Slater J, et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. Journal of Epilepsy 1992;5(1):55-60. 3168984
8. Rastogi P, Mehrotra TN, Agarwala RK, Singh VS. Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India 1991;39(8):606-8. 3168986
9. Shakir RA, Johnson RH, Lambie DG, Melville ID, Nanda RN. Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia 1981;22:27-33. 3168988
10. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatrics 1996;33:549-55. 3168990
11. Turnbull DM, Howel D, Rawlins MD, Chadwick DW. Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ 1985;290:815-9. 3168992
12. Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Developmental Medicine and Child Neurology 1993;35:149-57. 3168994
13. Callaghan N, O'Neill B, Kenny RA. A comparison between carbamazepine, phenytoin and sodium valproate as single drug treatment in epilepsy [abstract]. Irish Journal of Medical Science 1981;150(6):194. 3168996
14. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A comparative study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy: a preliminary communication. British Journal of Clinical Practice 1983;27:7-9. 3168998
15. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A comparative study of carbamazepine, sodium valproate and phenytoin as monotherapy in epilepsy: an updated report [abstract]. Irish Journal of Medical Science 1984;153(4):154. 3169000
16. Craig IR, Tallis RC. The impact of sodium valproate and phenytoin on cognitive function in elderly patients: results of a single-blind comparative study. Age and Ageing 1993;22(Suppl 2):10. 3169002
17. Czapinski P, Terczynski A, Czapinska E. Comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PB) and carbamazepine (CBZ) in patients with newly diagnosed epilepsy with partial complex seizures [abstract]. Journal of Neurology 1997;244(Suppl 3):S95-6. 3169004
18. Czapinski P, Terczynski A, Czapinska E. Randomized 36-month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences 1997;150(Suppl):S162-3. 3169006
19. Goggin T. A re-appraisal by control and seizure type of serum levels in previously untreated patients taking part in a prospective study comparing sodium valproate, phenytoin and carbamazepine as mono-therapy in epilepsy [abstract]. Irish Journal of Medical Science 1984;153(4):154. 3169008
20. Goggin T, Casey C, Callaghan N. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Medical Journal 1986;79(6):150-6. 3169010
21. Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia 2000;41(2):222-30. 3169012
22. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy and Behaviour 2003;4(6):659-66. 3169014
23. Sabers A, Møller A, Dam M, Smed A, Arlien-Søborg P, Buchman J, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurologica Scandinavica 1995;92(1):19-27. 3169016
24. Schmidt D. How reliable is early treatment response in predicting long-term seizure outcome?. Epilepsy and Behaviour 2007;10(4):588-94. 3169018
25. Shakir RA. Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. Royal Society of Medicine International Congress and Symposium 1980;30:7-16. 3169020
26. Tallis R, Craig I, Easter D. Multicentre comparative trial of sodium valproate and phenytoin in elderly patients with newly diagnosed epilepsy. Age and Ageing 1994;23:S5. 3169022
27. Tallis R, Easter D. Multicenter comparative trial of valproate and phenytoin. Epilepsia 1994;35(Suppl 7):62. 3169024
28. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. Journal of Neurology, Neurosurgery and Psychiatry 1982;45(1):55-9. 3169026
29. Wilder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983;33(11):1474-6. 3169028
30. Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clinical Neurology and Neurosurgery 2010;112:291-5. 3169030
31. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502-6.
32. Bodensteiner JB, Brownsworth RD, Knapik JR, Kanter MC, Cowan LD, Leviton A. Interobserver variability in the ILAE classification of seizures in childhood. Epilepsia 1988;29(2):123-8.
33. Bourgeois B, Beaumanoir A, Blajev B, Cruz ND, Despland PA, Egli M, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28(Suppl 2):S8-11.
34. Brasfield KH. Pilot study of divalproex sodium valproate versus valproic acid: drug acquisition costs versus all related costs. Current Therapeutic Research 1999;60(3):138-44.
35. Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, García-Fiñana M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery and Psychiatry 2013;84(6):637-43. [DOI: 10.1136/jnnp-2012-304270]
36. Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2]
37. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, et al. Malformations in offspring of women with epilepsy: A prospective study. Epilepsia 1999;40(9):1231-6.
38. Carl GF, Smith ML. Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia 1992;33(2):372-5.
39. Chadwick DW. Valproate in the treatment of partial epilepsies. Epilepsia 1994;35(5):S96-8.
40. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4.
41. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489-501.
42. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
43. Cranor CW, Sawyer WT, Carson SW, Early JJ. Clinical and economic impact of replacing divalproex sodium with valproic acid. American Journal of Health-System Pharmacy 1997;54:1716-22.
44. Delgado-Escueta AV, Enrile-Bascal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34(3):285-94.
45. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurologica Scandinavica 1984;69:65-9.
46. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine-a reappraisal. Seizure 1997;6(2):121-5.
47. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283(6291):577-81.
48. Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology 1992;6(3):257-61.
49. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984. Epilepsia 1993;34:453-68.
50. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
51. Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
52. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders?. Neurology 2007;68:326-37.
53. ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39(7):799-803.
54. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: Evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094-120.
55. Jeavons PM. Choice of drug therapy in epilepsy. Practitioner 1977;219:542-56.
56. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36-9.
57. Juul-Jenson P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24:297-312.
58. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
59. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342:314-9.
60. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
61. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35(5):1026-8.
62. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JWA, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology 2000;48:833-41.
63. Malafosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R, editor(s), et al. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic Aspects. Eastleigh: John Libbey and Company, 1994. [0861964365]
64. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001030]
65. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985;313(3):145-51.
66. Meador K, Reynolds M, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81:1-13.
67. Morrow J, Russel A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Journal of Neurology, Neurosurgery and Neuropsychiatry 2006;77(2):193-8.
68. Murray CJL, Lopez AD, World Health Organization. Global comparative assessments in the health sector: disease burden, expenditures and intervention packages. apps.who.int/iris/handle/10665/41177 (accessed 01 08 2018).
69. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson A. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database of Systematic Reviews 2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3]
70. Nevitt SJ, Marson AG, Weston J, Tudur-Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3]
71. Nevitt SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 6. [DOI: 10.1002/14651858.CD001031.pub4]
72. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-90.
73. National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. www.nice.org.uk/guidance/cg137 (accessed 01 08 2018).
74. Nolan SJ, Muller M, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD003615.pub3]
75. Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2]
76. Nolan SJ, Sutton L, Marson A, Tudur Smith C. Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health, Quebec City. 2013:114-5.
77. Nolan SJ, Sudell M, Tudur Smith C, Marson A. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD012065.pub2]
78. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub2]
79. Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. Journal of Child Neurology 1999;14(8):490-5.
80. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics 1997;68(1):18-24.
81. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorfer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4:627-34.
82. Ornoy A. Valproic acid in pregnancy: How much are we endangering the embryo and fetus?. Reproductive Toxicology 2009;28(1):1-10.
83. Ottman R, Lee JH, Hauser WA, Hong S, Hesdorffer D, Schupf N, et al. Reliability of seizure classification using a semistructured interview. Neurology 1993;43(12):2526-30.
84. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
85. Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long term response to therapy. Epilepsia 1989;30(Suppl 4):S19-23.
86. Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61(5):433-43.
87. Sander JW. The use of anti-epileptic drugs - principles and practice. Epilepsia 2004;45(6):28-34.
88. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512-21.
89. Scheinfeld N. Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects. Dermatology Online Journal 2003;9(3):6.
90. Schünemann H, Brozek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. GRADE Working Group, 2013.
91. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.
92. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10(7):609-17.
93. Troupin AS, Ojemann LM. Paradoxical intoxication - a complication of anticonvulsant administration. Epilepsia 1975;16:753-8.
94. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007;5(8):34.
95. Vallarta JM, Bell DB, Reichert A. Progressive encephalopathy due to chronic hydantoin intoxication. American Journal of Diseases of Children 1974;128:27-34.
96. Wallace H, Shorvon SD, Hopkins A, O'Donoghue M. National Society of Epilepsy Guidelines. London: Royal College of Physicians 1997.
97. Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews 2017, Issue 4. [DOI: 10.1002/14651858.CD010224.pub2]
98. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology 1983;33:808-11.
99. Wilder BJ. Phenytoin: clinical use. Antiepileptic Drugs. New York: Raven Press, 1995:339-44.
100. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick DW. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice 2000;6(2):205-14.
101. Williamson PR, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(11):3337-51.
102. Nolan SJ, Marson AG, Pulman J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD001769.pub2]
103. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD001769.pub3]
104. Tudur C, Ramaratnam S, Marson AG, Williamson PR, Hutton JL, Chadwick DW. Phenytoin vs sodium valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001769]
105. Tudur Smith C, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD001769]